In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East, which took place in Philadelphia last week. The event brought together marketing experts from across the life sciences industry. 

Fierce Pharma Marketing's Andrea Park and Ben Adams talk about major trends from the event that came up in conversations, including the complicated current attitudes toward artificial intelligence in this space. 

They also highlight some winners of the annual Fierce Pharma Marketing Awards, held on the final night of Digital Pharma East.  

To learn more about the topics in this episode: 
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Pfizer, Sanofi, GSK among the winners of the 2024 Fierce Pharma Marketing Awards
Two-thirds of top 20 pharmas have banned ChatGPT—and many in life sci call AI 'overrated,' survey finds

In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East, which took place in Philadelphia last week. The event brought together marketing experts from across the life sciences industry. 
Fierce Pharma Marketing's Andrea Park and Ben Adams talk about major trends from the event that came up in conversations, including the complicated current attitudes toward artificial intelligence in this space. 
They also highlight some winners of the annual Fierce Pharma Marketing Awards, held on the final night of Digital Pharma East.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/marketing/navigating-ai-hype-cycle-bayer-daiichi-sankyo-and-argenx-leaders-implementing-ai">Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing</a></li>
<li><a href="https://www.fiercepharma.com/marketing/pfizer-sanofi-gsk-among-winners-2024-fierce-pharma-marketing-awards">Pfizer, Sanofi, GSK among the winners of the 2024 Fierce Pharma Marketing Awards</a></li>
<li><a href="https://www.fiercepharma.com/marketing/two-thirds-top-20-pharmas-have-banned-chatgpt-and-many-life-sci-call-ai-overrated-survey">Two-thirds of top 20 pharmas have banned ChatGPT—and many in life sci call AI 'overrated,' survey finds</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Recapping Digital Pharma East 2024

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculated on what the legislation could mean for the life sciences industry. 

In this week's episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner sits down with Arnold & Porter’s Life Sciences practice chair Dan Kracov to discuss the broader implications of the bill, and what the likely next steps are for the legislation to become law. 

Kracov also breaks down what measures life sciences companies are already taking in light of the bill and concessions that may need to be made to appease lawmakers on both sides of the aisle.  

To learn more about the topics in this episode: 
After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned
Despite looming BIOSECURE threat, pharma contracting giant WuXi Bio scoops up new projects
Lawmakers urge FDA to investigate clinical trials run in tandem with China's military

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculated on what the legislation could mean for the life sciences industry. 
In this week's episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner sits down with Arnold &amp; Porter’s Life Sciences practice chair Dan Kracov to discuss the broader implications of the bill, and what the likely next steps are for the legislation to become law. 
Kracov also breaks down what measures life sciences companies are already taking in light of the bill and concessions that may need to be made to appease lawmakers on both sides of the aisle.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/china-focused-biosecure-act-passes-house-heres-what-targeted-companies-are-saying">After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned</a></li>
<li><a href="https://www.fiercepharma.com/pharma/crdmo-wuxi-biologics-continues-scoop-western-contracts-despite-looming-biosecure-concerns">Despite looming BIOSECURE threat, pharma contracting giant WuXi Bio scoops up new projects</a></li>
<li><a href="https://www.fiercepharma.com/pharma/amid-biosecure-brouhaha-house-committee-urges-fda-investigate-clinical-trials-run-tandem">Lawmakers urge FDA to investigate clinical trials run in tandem with China's military</a></li>
</ul>

Breaking down BIOSECURE—Industry implications and what comes next

At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate. 

In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.   

To learn more about the topic in this episode: 
iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field

At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate. 
In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.   
To learn more about the topic in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/esmo-iteos-gsks-tigit-star-shows-30-more-tumor-shrinkage-jemperli-ph-2">iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors</a></li>
<li><a href="https://www.fiercepharma.com/pharma/akeso-summit-pd-1-bispecific-crushes-merck-keytruda-new-standard-lung-cancer">Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/cooking-gas-regenerons-opdualag-rival-companys-next-big-thing-solid-tumor-treatments">'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors</a></li>
<li><a href="https://www.fiercepharma.com/pharma/bristol-myers-moves-opdualag-phase-3-trials-competitive-first-line-lung-cancer-field">ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field</a></li>
</ul>

ESMO, WCLC lung cancer data spark hope—and debate

In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. 

We share the stories of a select few 2024 Fierce 50 honorees and interesting highlights from this year's special report. 

To learn more about the topics in this episode: 


Fierce 50 of 2024 


Innovation Honorees


Health Equity Honorees


Social Impact Honorees


Breakthroughs Honorees
Patient Advocacy Honorees

In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. 
We share the stories of a select few 2024 Fierce 50 honorees and interesting highlights from this year's special report. 
To learn more about the topics in this episode: 
<ul>
<li>
<a href="https://www.fiercepharma.com/collection/fierce-50-2024">Fierce 50 of 2024 </a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/innovation">Innovation Honorees</a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/health-equity">Health Equity Honorees</a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/social-impact">Social Impact Honorees</a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/breakthroughs">Breakthroughs Honorees</a>
</li>
<li><a href="https://www.fiercepharma.com/book/patient-advocacy">Patient Advocacy Honorees</a></li>
</ul>

Recapping Digital Pharma East 2024

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips